Value investing is easily one of the most popular ways to find great stocks in any market environment. After all, who wouldn't want to find stocks that are either flying under the radar and are compelling buys, or offer up tantalizing …
NASDAQ11mon
Mylan's EpiPen price hikes made it the face of corporate greed last summer. Now, the drug maker is lavishing a top exec with an eye-popping pay package. Despite the EpiPen scandal and a slumping stock price, Mylan (MYL) rewarded …
Mylan could be facing another issue when it comes to the EpiPen, a drug used to treat severe allergic reactions that …
The generic drug company's move is a blow to the Tel Aviv Stock Exchange's recovery prospects. Generic drugs company Mylan has announced its intention of delisting from the Tel Aviv Stock Exchange. Mylan has been traded in Tel Aviv …
Eleven states require schools to stock epinephrine, according to Food Allergy Research & Education, an allergy advocacy group that counts Mylan as one of its corporate sponsors. A provision in the Federal Aviation Administration …
Abbott Laboratories (NYSE: ABT) has agreed to sell its non-U.S. generic drug business to Mylan Inc. (NASDAQ: MYL) in an all-stock transaction valued at $5.3 billion. Mylan will form a new company based in the Netherlands, of which …
Shares of Mylan Laboratories fell 5 percent yesterday, to $18.38, after regulatory scrutiny of a crucial product late last week and a day after the financier Carl C. Icahn offered to sell his stock in the company. Mr. Icahn, who has offered to …
Stringer, who manages the city’s five pension funds that own more than a million shares of Mylan stock worth $45 million, sent a letter to the company demanding corporate governance reform to boost oversight and accountability. The five city …
A rating of 3 would signify a consensus Hold recommendation. Investors who are keeping close eye on Mylan N.V. …